EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B


, : The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. Journal of Infection 22(1): 45-52

In a randomised clinical trial, we compared the efficacy of the new triazole drug itraconazole (200 mg orally twice daily) with that of amphotericin B (0.6 mg/kg daily or 0.3 mg/kg in combination with flucytosine) in neutropenic (less than 500 x 10(6)/l neutrophils) patients with proven or highly suspected systemic fungal infections. Patients with unexplained fever alone were not included in the study. Of the 40 patients enrolled, 32 patients (16 males, 16 females) were evaluable. Sixteen patients (median age 49 years) were treated with itraconazole for a median period of 20 days and 16 patients (median age 32 years) received amphotericin B for a median period of 13 days. The overall clinical response was 10/16 (63%) for patients treated with itraconazole and 9/16 (56%) for patients treated with amphotericin B (P greater than 0.90). Itraconazole seemed to be more effective against Aspergillus infections, whereas amphotericin B seemed to be more effective against candidal infections, although the differences were not statistically significant.

Accession: 002249703

PMID: 1848268

DOI: 10.1016/0163-4453(91)90954-q

Download PDF Full Text: The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

van't Wout, J.W.; Novakova, I.; Verhagen, C.A.; Fibbe, W.E.; de Pauw, B.E.; van der Meer, J.W., 1991: The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. In a randomised clinical trial, we compared the efficacy of the new triazole drug itraconazole (200 mg orally twice daily) with that of amphotericin B (0.6 mg/kg daily or 0.3 mg/kg in combination with flucytosine) in neutropenic (less than 500 x 1...

Wout, J.W. van' t; Novakova, I.; Verhagen, C.A.H.; Fibbe, W.E.; Pauw, B.E. de; Meer, J.W.M. van der, 1991: Treatment of systemic mycoses in neutropenic patients with itraconazole. A comparative, randomised study with amphotericin B. A case is reported in a 16-yr-old, neutropenic boy with disseminated Aspergillus fumigatus infection who was successfully treated with itraconazole. The results of a randomized comparative investigation into the efficacy of amphotericin B and itra...

Bodhe, P.V.; Kotwani, R.N.; Kirodian, B.G.; Kshirsagar, N.A.; Pandya, S.K., 2002: Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection. To compare conventional amphotericin B (c-amp B) and liposomal amphotericin B (L-AMP-LRC-1-India) in patients with systemic fungal infection in open, randomized, comparative, laboratory blind, phase III safety and efficacy study. Formulation of li...

van't Wout, J.W.; Novakova, I.; Verhagen, C.A.; Fibbe, W.E.; de Pauw, B.E.; van der Meer, J.W., 1991: Therapy of systemic mycoses in neutropenic patients using itraconazole. A comparative, randomized study with amphotericin B. Systemic mycosis constitute a serious threat for the patient with granulocytopenia. The most important causative agents are Candida spp., Aspergillus spp. and, to a lesser extent, Cryptococcus neoformans, Mucoraceae and Pseudoallescheria boydii. T...

Nucci, M.; Pulcheri, W.; Bacha, P.C.; Spector, N.; Caiuby, M.J.; Costa, R.O.; de Oliveira, H.P., 1994: Amphotericin B followed by itraconazole in the treatment of disseminated fungal infections in neutropenic patients. The role of the new triazoles in the treatment of disseminated fungal infections in neutropenic patients is at present under scrutiny. Six neutropenic patients with disseminated fungal infections were treated with amphotericin B during neutropenia...

Boogaerts, M.; Maertens, J.; van Hoof, A.; de Bock, R.; Fillet, G.; Peetermans, M.; Selleslag, D.; Vandercam, B.; Vandewoude, K.; Zachée, P.; D.B.ule, K., 2001: Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. The efficacy and safety of itraconazole oral solution and a combination of amphotericin B capsules plus nystatin oral suspension were compared in the prophylaxis of fungal infections in neutropenic patients [Belgium]. In an open, randomized, multi...

Myint, H.; Kyi, A.A.; Winn, R.M., 1998: An open, non-comparative evaluation of the efficacy and safety of amphotericin B lipid complex as treatment of neutropenic patients with presumed or confirmed pulmonary fungal infections. Journal of Antimicrobial ChemoTherapy 41(3): 424-426

Thunnissen, P.L.; Sizoo, W.; Hendriks, W.D., 1991: Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. In a non-randomized study the efficacy of itraconazole in preventing fungal infections in neutropenic patients was investigated. Forty-seven patients with acute leukemia or advanced lymphoblastic lymphoma were enrolled. Ninety-two episodes of seve...

Vreugdenhil, G.; Van Dijke, B.J.; Donnelly, J.P.; Novakova, I.R.; Raemaekers, J.M.; Hoogkamp-Korstanje, M.A.; Koster, M.; de Pauw, B.E., 1993: Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. The efficacy and safety of itraconazole in the prevention of mycoses was investigated in neutropenic patients from the University Hospital, Nijmegen, Netherlands, who were given cytotoxic chemotherapy for haematological malignancies. Patients (n=9...

Moeremans, K.; Annemans, L.; Ryu, J-So.; Choe, K-Won.; Shine, W-Shik., 2005: Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea. Systemic fungal infections remain a major clinical problem in immunocompromised patients. Presumed systemic fungal infections (PSFI) are treated empirically with an intravenous antifungal agent to reduce the occurrence of documented infections and...